Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

NCT07038629 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: S1
DRUG: Iparomlimab
RADIATION: Radiation

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]
[object Object]